Trial Profile
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs MB 102 Mustang Bio (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
- Focus Adverse reactions; First in man; Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2024.
- 07 Sep 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.